Investors focused on the Finance space have likely heard of Chimera Investment (CIM), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.Chimera Investment is a member of the Finance sector. This group includes 900 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CIM is currently sporting a Zacks Rank of #2 (Buy).Within the past quarter, the Zacks Consensus Estimate for CIM's full-year earnings has moved 40% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.According to our latest data, CIM has moved about 46.54% on a year-to-date basis. Meanwhile, stocks in the Finance group have gained about 21.26% on average. This means that Chimera Investment is outperforming the sector as a whole this year.To break things down more, CIM belongs to the REIT and Equity Trust industry, a group that includes 34 individual companies and currently sits at #165 in the Zacks Industry Rank. On average, stocks in this group have gained 18.01% this year, meaning that CIM is performing better in terms of year-to-date returns.Investors with an interest in Finance stocks should continue to track CIM. The stock will be looking to continue its solid performance. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Chimera Investment Corporation (CIM): Free Stock Analysis Report To read this article on Zacks.com click here.